Ibutamoren (MK-677)
Neutral, BioHarmony verdict
BioHarmony score 4.9 out of 10
MK-677 (ibutamoren) is an oral, once-daily growth-hormone secretagogue that raises IGF-1 by about 50 to 97 percent and adds roughly 1.1 kg of fat-free mass, per the Nass 2008 two-year trial, but it also raises fasting glucose and never won FDA approval.
Read full reportWhat is Ibutamoren (MK-677)?
MK-677, also called ibutamoren, is an oral, once-daily growth-hormone secretagogue that lands at 4.5-5.0/10, Neutral, because its real strengths and real harms almost perfectly cancel out. It works by activating the ghrelin receptor, which nudges your own pituitary to release more growth hormone and raises IGF-1 into the young-adult range, per Patchett 1995. What makes it stand out from the injectable peptides people compare it to is the evidence behind it. It has been through multiple double-blind, placebo-controlled human trials, including a 2-year study and a 563-patient pivotal trial. That is far more human data than most things in this category have.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Agonist at the growth-hormone-secretagogue receptor (GHS-R1a), the same receptor ghrelin uses
Safety watch-outs
- Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes or pre-diabetes.
- New edema or any breathlessness, ankle swelling, or unusual fatigue: stop, given the documented congestive-heart-failure signal.
- Any active or suspected cancer: do not use, because growth-hormone and IGF-1 signaling can promote proliferation.
- Carpal-tunnel-type numbness or tingling that worsens: reduce the dose or stop.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Ibutamoren (MK-677) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA places ibutamoren mesylate in Category 2 for 503A and 503B compounding and identifies a potential congestive-heart-failure safety signal.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risks U.S. Food and Drug Administration,
Related peptides for recovery & tissue repair
- 7.4Thymosin Alpha-1Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD…
- 7.2GHK-Cu (Copper Peptide)GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
- 7.1SemaxSemax is a Russian-developed ACTH 4-7 + PGP heptapeptide with the strongest human signal in post-stroke recovery, including a 110-patient Gusev et al.
- 6.9Thymosin Beta-4 (Full)Thymosin beta-4 is the native 43-amino-acid peptide that promotes tissue repair via actin-sequestering and the Ac-SDKP repair axis.
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.